On April 2, 2026, Jade Biosciences, Inc. announced the approval of its 2026 Employment Inducement Stock Incentive Plan by the Board of Directors. This plan is designed to attract and retain talented employees by providing stock options and restricted stock units as part of their compensation package. The terms of the new plan are largely similar to those of the previous 2025 Stock Incentive Plan, with the notable exception that incentive stock options will not be issued under the new plan. Instead, awards can only be granted to eligible recipients as defined by Nasdaq rules. The Board has reserved 1,750,000 shares of common stock for issuance under this plan, which was adopted without stockholder approval in accordance with Nasdaq Listing Rules. This strategic move is expected to enhance the company's ability to attract new talent, particularly those who have not previously been employed by Jade Biosciences or its subsidiaries. The company plans to file a complete copy of the 2026 Inducement Plan along with the forms of stock option agreement and restricted stock unit agreement as exhibits to its upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2026. This initiative reflects Jade Biosciences' commitment to strengthening its workforce and ensuring operational execution in a competitive market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.